Functional Ingredients

Helinorm - (Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri (Pylopass))

Therapeutic Segment – Eradication therapy of Helicobactor Pylori

Production Technology (API) – Fermentation of L. reuteri DSM 17648 followed by cell harvest and drying.

Dosage Form – Capsules

Innovator – Novozymes A/S, Denmark

Mechanism of Action

With its highly targeted mode of action, Helinorm( L. reuteri DSM17648 strain) recognizes and adheres to H. pylori cell surface structures, thereby forming a mass of L. reuteri DSM 17648 and H. pylori cells, known as a co-aggregate. The co-aggregates travel through the gastrointestinal system and the reduction in H. pylori is a result of the co-aggregates being washed away. Through this unique and sophisticated mode of action, Helinorm works in a safe and highly targeted way, and can help to reduce the load of H. pylori cells in the stomach.

Indications

Helinorm is intended to be used for H. Pylori eradication therapy of 14 days.